CHU Nancy
Vandœuvre-lès-Nancy, Grand Est, 54500, France
Location status: Recruiting
NCT Number: NCT05345795
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. In patients with systemic sclerosis, interstitial lung disease (ILD) concerns almost 50 % of patients and represents the main cause of mortality. Disease course in SSc-ILD is highly variable: patients can experience stable disease, slow or fast progression. Prevention of ILD progression now represents a key objective of SSc-ILD management. The understanding of the course and patterns of SSc-ILD progression is necessary, as reliable prediction tools that allow the stratification of the risk of progression. We aimed to identify the longitudinal trajectories of ILD in SSc patients using latent class mixed models and to examine their associations with SSc characteristics.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Vandœuvre-lès-Nancy, Grand Est, 54500, France
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: at ILD diagnosis (Day 0) and within 5 years after ILD diagnosis
evaluation of %predicted FVC values over time using latent class mixed models (LCMM)
Time frame: at ILD diagnosis (Day 0) and within 5 years after ILD diagnosis
evaluation of %predicted DLCO values over time using latent class mixed models (LCMM)
Contact information is provided by the study sponsor or research team.
Central Hospital, Nancy, France
Other
Evaluation of Interstitial Lung Disease Trajectories in Patients With Systemic Sclerosis (SCLEROPIDEVOL Study)
Acronym: SCLEROPIDEVOL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06297096
Connective Tissue Diseases, Interstitial Lung Disease
Warsaw, Masovian Voivodeship, Poland
View Trial DetailsNCT05785065
Connective Tissue Diseases, Interstitial Lung Disease
Montreal, Quebec, Canada
View Trial DetailsNCT05482607
Connective Tissue Diseases, Interstitial Lung Disease
Nancy, France
View Trial DetailsNCT05007340
Arthritis, Autoimmune Diseases
Montreal, Quebec, Canada
View Trial Details